CP-690-550 Ointment For Chronic Plaque Psoriasis

Pfizer

Status and phase: Completed; Phase 2

Conditions: Psoriasis

Treatments: Drug: Vehicle 1; Drug: CP-690,550 Ointment 2; Drug: Vehicle 2; Drug: CP-690,550 Ointment 1

Study type: Interventional

Funder types: Industry

Identifiers

NCT01246583

A3921116

Details and patient eligibility

About

The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.

Enrollment: 71 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months;
• A target plaque of at least 9 sq. cm.

Exclusion criteria

• Demonstrates "rebound" or "flare" of chronic plaque psoriasis;
• Non plaque form of psoriasis;
• Currently have or history of psoriatic arthritis;
• Current drug induced psoriasis;
• Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months;
• Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

71 participants in 4 patient groups, including a placebo group

Treatment Group A

Experimental group

Treatment:

Drug: CP-690,550 Ointment 1

Treatment Group B

Placebo Comparator group

Treatment:

Drug: Vehicle 1

Treatment Group C

Experimental group

Treatment:

Drug: CP-690,550 Ointment 2

Treatment Group D

Placebo Comparator group

Treatment:

Drug: Vehicle 2